H2 receptor antagonists (H2 blockers) were developed for gastric acid suppression but have immunomodulatory properties relevant to ME/CFS. Cimetidine in particular has been studied for viral infections (see Section cimetidine antiviral synergy).
Cimetidine vs. Famotidine: Critical Differences
While both are H2 blockers, cimetidine and famotidine have important differences for ME/CFS patients:
| Minimal |
CYP450 inhibition |
Strong (1A2, 2D6, 3A4) |
Minimal |
CNS penetration |
| Moderate |
Lower |
Psychiatric effects |
Rare |
Reported (see below) |
Clinical implication: Famotidine cannot be substituted for cimetidine when immunomodulation is the therapeutic goal. However, for pure acid suppression in patients requiring CYP450-metabolized medications, famotidine is preferred.
H2 receptor antagonists can cause psychiatric adverse effects, including depression and suicidal ideation. While these are rare, they appear more frequent in patients with the “paradoxical reactor” phenotype (see Section Medication Sensitivity Phenotypes).
Famotidine-specific risk: Despite lower CNS penetration than cimetidine, famotidine has been associated with severe psychiatric reactions in susceptible individuals. Notably, some patients tolerate cimetidine but not famotidine, suggesting drug-specific rather than class-wide effects.
Risk factors:
- History of paradoxical medication reactions
- Pre-existing mood disorders
- Concurrent use of other CNS-active medications
- ME/CFS with prominent neurological features
Monitoring:
- Screen for mood changes during first 2–4 weeks
- Ensure caregiver/family awareness for early detection
- Discontinue immediately if depressive symptoms or suicidal ideation emerge
- If famotidine causes psychiatric effects, do not assume cimetidine will also—trial may be warranted
Aspirin is contraindicated in patients with histamine intolerance (HIT).
Aspirin inhibits platelet cyclo-oxygenase, which reduces platelet-mediated histamine inactivation. This mechanism causes aspirin to trigger histamine release and block histamine metabolism, significantly worsening symptoms in patients with HIT or MCAS.
For ME/CFS patients with confirmed HIT or MCAS-overlap phenotype:
- Avoid aspirin entirely (including low-dose “cardioprotective” regimens)
- Avoid other NSAIDs: They share similar histamine-liberating effects
- Use alternatives for pain management: Acetaminophen, PEA (palmitoylethanolamide), topical analgesics
- Communicate with prescribers: Clearly document HIT status to prevent inadvertent aspirin prescription
This contraindication applies regardless of cardiovascular indication, as the histamine burden outweighs cardioprotective benefit.
Cimetidine-LDN Synergy Protocol for Viral-Immune-Phenotype ME/CFS
For patients with evidence of viral-immune phenotype (elevated EBV titers, history of viral trigger, strong response to cimetidine alone), combining cimetidine with low-dose naltrexone may address both viral-immune and neuroinflammatory pathways.
Cimetidine vs. Famotidine: Critical Differences
H2 receptor antagonists can cause psychiatric adverse effects, including depression and suicidal ideation. While these are rare, they appear more frequent in patients with the “paradoxical reactor” phenotype (see Section Medication Sensitivity Phenotypes).
Famotidine-specific risk: Despite lower CNS penetration than cimetidine, famotidine has been associated with severe psychiatric reactions in susceptible individuals. Notably, some patients tolerate cimetidine but not famotidine, suggesting drug-specific rather than class-wide effects.
Risk factors:
- History of paradoxical medication reactions
- Pre-existing mood disorders
- Concurrent use of other CNS-active medications
- ME/CFS with prominent neurological features
Monitoring:
- Screen for mood changes during first 2–4 weeks
- Ensure caregiver/family awareness for early detection
- Discontinue immediately if depressive symptoms or suicidal ideation emerge
- If famotidine causes psychiatric effects, do not assume cimetidine will also—trial may be warranted
Aspirin is contraindicated in patients with histamine intolerance (HIT).
Aspirin inhibits platelet cyclo-oxygenase, which reduces platelet-mediated histamine inactivation. This mechanism causes aspirin to trigger histamine release and block histamine metabolism, significantly worsening symptoms in patients with HIT or MCAS.
For ME/CFS patients with confirmed HIT or MCAS-overlap phenotype:
- Avoid aspirin entirely (including low-dose “cardioprotective” regimens)
- Avoid other NSAIDs: They share similar histamine-liberating effects
- Use alternatives for pain management: Acetaminophen, PEA (palmitoylethanolamide), topical analgesics
- Communicate with prescribers: Clearly document HIT status to prevent inadvertent aspirin prescription
This contraindication applies regardless of cardiovascular indication, as the histamine burden outweighs cardioprotective benefit.
Cimetidine-LDN Synergy Protocol for Viral-Immune-Phenotype ME/CFS
Cimetidine immunomodulation:
- Blocks H2 receptors on suppressor T cells, enhancing cellular immune function
- Increases NK cell activity and T cell cytotoxicity against EBV and HHV-6
- Reduces viral-mediated immune suppression
- Direct mechanism: H2 receptor antagonism → enhanced Th1/Tc1 response against intracellular pathogens
LDN neuroinflammation reduction:
- Modulates TLR4 signaling on microglia, reducing neuroinflammatory cytokines (IL-6, TNF-\(\alpha\))
- May reduce microglial activation secondary to viral-driven immune activation
- Addresses downstream neurological consequences while cimetidine addresses upstream viral driver
Synergistic rationale: The combination targets two complementary mechanisms:
- Viral control: Cimetidine enhances immune clearance capacity against persistent herpesviruses
- Neuroinflammation reduction: LDN modulates microglial response, reducing secondary neurological damage
- Dual targeting: Two-pronged approach may produce more complete viral suppression and superior symptomatic improvement than either agent alone
This mechanism may explain why some patients report dramatic response to cimetidine alone but plateau at partial improvement, while combination with LDN may extend recovery further. (This combination rationale is inferred from individual case reports, not controlled trial data.)
Patient Selection:
This protocol is appropriate for patients demonstrating:
- Clear post-viral onset (documented EBV infection, mononucleosis, or severe flu-like illness at disease onset)
- Elevated EBV serology (VCA IgG >750 mIU/mL, EA-D present, or positive PCR for EBV/HHV-6)
- Dramatic response to cimetidine trial (≥50% improvement in energy and function)
- No contraindication to LDN (see Warning LDN Psychiatric Adverse Effects)
Phase 1: Establish Cimetidine Baseline (Weeks 1–4)
- Cimetidine dose: 200 mg twice daily (400 mg total daily)
- Assessment at Week 4: Document improvement in energy, symptom severity, hours out of bed
- Continuation criterion: If energy improved ≥25%, proceed to Phase 2
- Discontinuation criterion: If minimal response (<10% improvement), this phenotype unlikely; discontinue and pursue alternative pathway
Phase 2: Add LDN with Mood Monitoring (Weeks 5–12)
LDN initiation: Start 0.5 mg at bedtime (compounded low-dose form required)
Titration: Increase by 0.5 mg every 1–2 weeks toward target 3 mg at bedtime
Psychiatric monitoring: MANDATORY—LDN carries psychiatric adverse effect risk in subset of patients
- Daily mood assessment first 2 weeks
- PHQ-2 screening at each dose adjustment
- Caregiver/family observation for behavioral changes
- Immediate discontinuation if depression or suicidal ideation emerges
Continue cimetidine: Maintain 200 mg BID throughout LDN titration
Phase 3: Combination Assessment (Weeks 12–16)
At Week 12, evaluate the combination:
Response assessment: Compare current function to Phase 1 baseline (Week 4)
Expected improvement pattern:
- Energy/fatigue domain: Substantial improvement on cimetidine alone in responders; potential for further gains with LDN addition (magnitude varies; no controlled comparison data)
- Cognitive function: May show additional improvement (LDN-mediated microglial modulation)
- Pain/inflammation: May improve as neuroinflammation decreases
Non-response to combination: If combined therapy provides <10% additional benefit over cimetidine alone, consider discontinuing LDN; continue cimetidine alone
Psychiatric adverse effects: If mood changes emerged, discontinue LDN regardless of energy benefit
Phase 4: Viral Monitoring (ongoing)
If combination therapy shows improvement, assess viral response:
EBV serology: Repeat VCA IgG, EA-D at 12 weeks; assess for titers declining toward normal range
EBV PCR: If available, quantitative PCR to assess viral load suppression
Interpretation patterns:
- EBV titers decline + symptoms improve: Viral control achieved; continue combination indefinitely
- EBV titers decline without symptom improvement: Viral suppression necessary but not sufficient; add other interventions
- Symptoms improve without titers declining: May reflect improved immune tolerance rather than viral clearance; monitor for relapse
Maintenance Protocol (months 3+):
For sustained responders:
- Continue cimetidine 200–400 mg daily (dose adjusted to symptom stability)
- Continue LDN 3 mg at bedtime
- Reassess quarterly: symptoms, EBV titers, mood screening
- Plan gradual dose reduction after 12–18 months of stability if viral titers have normalized
H2 receptor antagonists can cause psychiatric adverse effects, including depression and suicidal ideation. While these are rare, they appear more frequent in patients with the “paradoxical reactor” phenotype (see Section Medication Sensitivity Phenotypes).
Famotidine-specific risk: Despite lower CNS penetration than cimetidine, famotidine has been associated with severe psychiatric reactions in susceptible individuals. Notably, some patients tolerate cimetidine but not famotidine, suggesting drug-specific rather than class-wide effects.
Risk factors:
- History of paradoxical medication reactions
- Pre-existing mood disorders
- Concurrent use of other CNS-active medications
- ME/CFS with prominent neurological features
Monitoring:
- Screen for mood changes during first 2–4 weeks
- Ensure caregiver/family awareness for early detection
- Discontinue immediately if depressive symptoms or suicidal ideation emerge
- If famotidine causes psychiatric effects, do not assume cimetidine will also—trial may be warranted
Aspirin is contraindicated in patients with histamine intolerance (HIT).
Aspirin inhibits platelet cyclo-oxygenase, which reduces platelet-mediated histamine inactivation. This mechanism causes aspirin to trigger histamine release and block histamine metabolism, significantly worsening symptoms in patients with HIT or MCAS.
For ME/CFS patients with confirmed HIT or MCAS-overlap phenotype:
- Avoid aspirin entirely (including low-dose “cardioprotective” regimens)
- Avoid other NSAIDs: They share similar histamine-liberating effects
- Use alternatives for pain management: Acetaminophen, PEA (palmitoylethanolamide), topical analgesics
- Communicate with prescribers: Clearly document HIT status to prevent inadvertent aspirin prescription
This contraindication applies regardless of cardiovascular indication, as the histamine burden outweighs cardioprotective benefit.
Cimetidine immunomodulation:
- Blocks H2 receptors on suppressor T cells, enhancing cellular immune function
- Increases NK cell activity and T cell cytotoxicity against EBV and HHV-6
- Reduces viral-mediated immune suppression
- Direct mechanism: H2 receptor antagonism → enhanced Th1/Tc1 response against intracellular pathogens
LDN neuroinflammation reduction:
- Modulates TLR4 signaling on microglia, reducing neuroinflammatory cytokines (IL-6, TNF-\(\alpha\))
- May reduce microglial activation secondary to viral-driven immune activation
- Addresses downstream neurological consequences while cimetidine addresses upstream viral driver
Synergistic rationale: The combination targets two complementary mechanisms:
- Viral control: Cimetidine enhances immune clearance capacity against persistent herpesviruses
- Neuroinflammation reduction: LDN modulates microglial response, reducing secondary neurological damage
- Dual targeting: Two-pronged approach may produce more complete viral suppression and superior symptomatic improvement than either agent alone
This mechanism may explain why some patients report dramatic response to cimetidine alone but plateau at partial improvement, while combination with LDN may extend recovery further. (This combination rationale is inferred from individual case reports, not controlled trial data.)
Patient Selection:
This protocol is appropriate for patients demonstrating:
- Clear post-viral onset (documented EBV infection, mononucleosis, or severe flu-like illness at disease onset)
- Elevated EBV serology (VCA IgG >750 mIU/mL, EA-D present, or positive PCR for EBV/HHV-6)
- Dramatic response to cimetidine trial (≥50% improvement in energy and function)
- No contraindication to LDN (see Warning LDN Psychiatric Adverse Effects)
Phase 1: Establish Cimetidine Baseline (Weeks 1–4)
- Cimetidine dose: 200 mg twice daily (400 mg total daily)
- Assessment at Week 4: Document improvement in energy, symptom severity, hours out of bed
- Continuation criterion: If energy improved ≥25%, proceed to Phase 2
- Discontinuation criterion: If minimal response (<10% improvement), this phenotype unlikely; discontinue and pursue alternative pathway
Phase 2: Add LDN with Mood Monitoring (Weeks 5–12)
LDN initiation: Start 0.5 mg at bedtime (compounded low-dose form required)
Titration: Increase by 0.5 mg every 1–2 weeks toward target 3 mg at bedtime
Psychiatric monitoring: MANDATORY—LDN carries psychiatric adverse effect risk in subset of patients
- Daily mood assessment first 2 weeks
- PHQ-2 screening at each dose adjustment
- Caregiver/family observation for behavioral changes
- Immediate discontinuation if depression or suicidal ideation emerges
Continue cimetidine: Maintain 200 mg BID throughout LDN titration
Phase 3: Combination Assessment (Weeks 12–16)
At Week 12, evaluate the combination:
Response assessment: Compare current function to Phase 1 baseline (Week 4)
Expected improvement pattern:
- Energy/fatigue domain: Substantial improvement on cimetidine alone in responders; potential for further gains with LDN addition (magnitude varies; no controlled comparison data)
- Cognitive function: May show additional improvement (LDN-mediated microglial modulation)
- Pain/inflammation: May improve as neuroinflammation decreases
Non-response to combination: If combined therapy provides <10% additional benefit over cimetidine alone, consider discontinuing LDN; continue cimetidine alone
Psychiatric adverse effects: If mood changes emerged, discontinue LDN regardless of energy benefit
Phase 4: Viral Monitoring (ongoing)
If combination therapy shows improvement, assess viral response:
EBV serology: Repeat VCA IgG, EA-D at 12 weeks; assess for titers declining toward normal range
EBV PCR: If available, quantitative PCR to assess viral load suppression
Interpretation patterns:
- EBV titers decline + symptoms improve: Viral control achieved; continue combination indefinitely
- EBV titers decline without symptom improvement: Viral suppression necessary but not sufficient; add other interventions
- Symptoms improve without titers declining: May reflect improved immune tolerance rather than viral clearance; monitor for relapse
Maintenance Protocol (months 3+):
For sustained responders:
- Continue cimetidine 200–400 mg daily (dose adjusted to symptom stability)
- Continue LDN 3 mg at bedtime
- Reassess quarterly: symptoms, EBV titers, mood screening
- Plan gradual dose reduction after 12–18 months of stability if viral titers have normalized